36 episodes
Off Script: A Pharma Manufacturing Podcast Pharma Manufacturing
-
- Nyheter
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing's print and online coverage, which follows the industry's biggest issues surrounding scale-up, technology innovations, regulations and more. Off Script is hosted by Pharma Manufacturing editors Karen Langhauser and Meagan Parrish.
-
Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation, Moderna and Metagenomi deal ends, Emergent announces layoffs [The good, the bad, the ugly]
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Neurocrine wins FDA nod for 'sprinkle' Ingrezza formulation The bad — Moderna, Metagenomi end gene editing collabThe ugly — Emergent announces layoffs, closes sites -
Novartis wins rare cancer pediatric indication, BMS layoffs, McKinsey under fire [The good, the bad, the ugly]
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Novartis wins rare cancer pediatric indication for LutatheraThe bad — BMS unveils cost-saving initiative, layoffsThe ugly — McKinsey under fire for alleged role in opioid crisis -
GSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly]
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — GSK antibiotic hits phase 3 goals in gonorrheaThe bad — Genentech ends $3B Adaptimmune T-cell collabThe ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination -
BMS schizophrenia drug shines, Novartis axes jobs, Lilly compounding suit dismissed [The good, the bad, the ugly]
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — BMS schizophrenia drug shines in phase 3 trialThe bad — Novartis to axe 680 jobsThe ugly — Lilly compounding suit dismissed -
2024 election's impact on manufacturing
Politics, whether we like them or not, weigh heavy on manufacturing’s future.
In case you haven’t heard, it is an election year! Which means, global trade, regulations, immigration, national security and taxation will all be part of the national discourse, and all of those topics touch on manufacturing in one way or another.
During this podcast, we will share a discussion courtesy of our sister brand, IndustryWeek, as part of their livestream program, Production Pulse. The broadcast features insights from Pharma Manufacturing’s chief content director Karen Langhauser as well as from editors on Machine Design and Food Processing. -
Basilea grabs FDA nod, Verve halts gene editing trial, Amylyx pulls ALS drug [The good, the bad, the ugly]
Editor's Review: Week of April 1Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Basilea Pharmaceutica receives FDA approval for its IV antibioticThe bad — Verve Therapeutics halts gene editing trial, againThe ugly — Amylyx removes ALS treatment from market